Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy.

Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation.

Fintel reports that on January 16, 2025, Stifel upgraded their outlook for ... 26,042K shares , representing a decrease of 1.28%. Wellington Management Group Llp holds 18,562K shares representing ...

Stifel Nicolaus assumed coverage on shares ... after acquiring an additional 74,194 shares during the period. Finally, Wellington Management Group LLP grew its stake in Altimmune by 27.5% in ...

Insulin delivery device maker Beta Bionics said on Wednesday it was targeting a valuation of as much as $615.9 million in its initial public offering in the United States, underscoring a gradual ...